• 
• 
• 
• 

FDA News and Drug Updates

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

FDA Grants Approval to Avapritinib for Patients with GIST

Supportive Care

Psychosocial Issues in Patients with Cancer: It’s Time for Real-World Interventions

Corbin Davis

Medical Cannabis in Patients with Advanced Cancer: Challenges Remain

Corbin Davis

Key Considerations for Implementing a Scalp Cooling Program

Dia Byrne, MSN, RN, ACNS-BC, OCN

View All Supportive Care Articles

Lung Cancer

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC

Phoebe Starr

November 25, 2019 – Oncology News & Updates

View All Lung Cancer Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

View All Conference Correspondent Articles

Most Popular Articles

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Web Exclusives - FDA Updates, In the News, Lung Cancer, Thyroid Cancer

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

Web Exclusives - FDA Updates, In the News, Sarcoma

Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations

Conference Correspondent  - ASH 2019 Post Wrap-Up

Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Conference Correspondent  - ASH 2019 Post Wrap-Up